Standard
Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer. / Urbanska, Edyta M.; Sørensen, Jens B.; Melchior, Linea C.; Costa, Junia C.; Santoni-Rugiu, Eric.
In:
JCO Precision Oncology, Vol. 6, No. 6, e2200040, 2022.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Urbanska, EM
, Sørensen, JB, Melchior, LC, Costa, JC
& Santoni-Rugiu, E 2022, '
Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer',
JCO Precision Oncology, vol. 6, no. 6, e2200040.
https://doi.org/10.1200/PO.22.00040APA
Urbanska, E. M.
, Sørensen, J. B., Melchior, L. C., Costa, J. C.
, & Santoni-Rugiu, E. (2022).
Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer.
JCO Precision Oncology,
6(6), [e2200040].
https://doi.org/10.1200/PO.22.00040Vancouver
Urbanska EM
, Sørensen JB, Melchior LC, Costa JC
, Santoni-Rugiu E.
Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer.
JCO Precision Oncology. 2022;6(6). e2200040.
https://doi.org/10.1200/PO.22.00040Author
Urbanska, Edyta M. ; Sørensen, Jens B. ; Melchior, Linea C. ; Costa, Junia C. ; Santoni-Rugiu, Eric. / Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer. In: JCO Precision Oncology. 2022 ; Vol. 6, No. 6.
Bibtex
@article{4d75f6bf27e44cee92c7395b89e59986,
title = "Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer",
author = "Urbanska, {Edyta M.} and S{\o}rensen, {Jens B.} and Melchior, {Linea C.} and Costa, {Junia C.} and Eric Santoni-Rugiu",
year = "2022",
doi = "10.1200/PO.22.00040",
language = "English",
volume = "6",
journal = "JCO Precision Oncology",
issn = "2473-4284",
publisher = "American Society of Clinical Oncology",
number = "6",
}
RIS
TY - JOUR
T1 - Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer
AU - Urbanska, Edyta M.
AU - Sørensen, Jens B.
AU - Melchior, Linea C.
AU - Costa, Junia C.
AU - Santoni-Rugiu, Eric
PY - 2022
Y1 - 2022
U2 - 10.1200/PO.22.00040
DO - 10.1200/PO.22.00040
M3 - Journal article
C2 - 35797511
VL - 6
JO - JCO Precision Oncology
JF - JCO Precision Oncology
SN - 2473-4284
IS - 6
M1 - e2200040
ER -
